GlassScriptPhysician profile
Hans E Yehnert
NPI 1518076199
$4,171.77
in general payments reported to CMS, 2019-2025
33 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $149 · 2021: $259 · 2022: $645 · 2023: $570 · 2024: $633 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.92 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.88 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $470.23 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $382.42 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $331.82 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Vifor Pharma, INC. | $321.07 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $273.27 | 2021-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $162.52 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $153.81 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $144.78 | 2022-2023 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $124.14 | 2019-2024 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $107.00 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $102.03 | 2019 | |
| Aurinia Pharma U.S., INC. | $96.10 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $95.49 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.06 | 2022-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68.02 | 2021-2024 | Benlysta |
| Horizon Therapeutics Plc | $45.05 | 2019-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $44.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.03 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $39.67 | 2025 | Keveyis |
| Apellis Pharmaceuticals, INC. | $39.63 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $38.04 | 2019-2025 | Velphoro |
| Scpharmaceuticals INC. | $37.42 | 2025 | |
| Abbvie INC. | $26.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $25.77 | 2019 | |
| Daiichi Sankyo INC. | $20.34 | 2024 | Injectafer |
| Novo Nordisk INC | $17.52 | 2025 | Ozempic |
| Lilly USA, LLC | $15.02 | 2024 | Jardiance |
| Shire North American Group INC | $13.71 | 2019 | |
| Shield Therapeutics INC | $13.29 | 2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $11.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Yehnert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.